用于体内评估艾美赛珠单抗功能的A型血友病小鼠模型
本研究建立了一种新型A型血友病小鼠模型,通过尾剪出血实验评估双特异性抗体艾美赛珠单抗的体内功能。FVIII缺陷小鼠在出血前24小时静脉注射艾美赛珠单抗,出血前5分钟输注人FIX和FX,该模型显示艾美赛珠单抗产生类似FVIII的活性,1.5 mg/kg及以上剂量显著减少出血,但与FVIII浓缩物相比减少不完全,且与低剂量FVIII联用可完全止血。
要点
- 新型A型血友病小鼠模型可体内评估艾美赛珠单抗功能。
- 艾美赛珠单抗1.5 mg/kg及以上剂量显著减少尾剪出血模型的失血。
- 艾美赛珠单抗与低剂量FVIII(5 U/kg)联用可完全止血。
核心结论
- 该小鼠模型可用于艾美赛珠单抗的进一步体内分析。
研究设计与样本
- 研究描述了一种新型小鼠模型:FVIII缺陷小鼠在尾剪出血前24小时静脉注射艾美赛珠单抗,出血前5分钟输注人FIX和FX。
主要发现
- 艾美赛珠单抗剂量0.5-10 mg/kg对应血药浓度0.7-19 mg/dL;人FIX和FX在100 U/kg剂量后水平分别为85和101 U/dL。
- 小鼠血浆在稀释活化部分凝血活酶时间和凝血酶生成试验中显示类似FVIII的活性,与含艾美赛珠单抗的人样本相似。
- 艾美赛珠单抗1.5 mg/kg及以上剂量在FVIII缺陷小鼠尾剪出血模型中显著减少失血,但与FVIII浓缩物治疗相比减少不完全,且不同剂量间疗效无差异。
- 从该模型推导出艾美赛珠单抗的类FVIII活性相当于FVIII剂量4.5 U/kg(即9.0 U/dL)。
- 艾美赛珠单抗与低剂量FVIII(5 U/kg)联用提供足够的叠加活性,实现完全止血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The bispecific antibody emicizumab is increasingly used for hemophilia A treatment. However, its specificity for human factors IX and X (FIX and FX) has limited its in vivo functional analysis to primate models of acquired hemophilia. Here, we describe a novel mouse model that allows emicizumab function to be examined. Briefly, FVIII-deficient mice received IV emicizumab 24 hours before tail-clip bleeding was performed. A second infusion with human FIX and FX, administered 5 minutes before bleeding, generated consistent levels of emicizumab (0.7-19 mg/dL for 0.5-10 mg/kg doses) and of both FIX and FX (85 and 101 U/dL, respectively, after dosing at 100 U/kg). Plasma from these mice display FVIII-like activity in assays (diluted activated partial thromboplastin time and thrombin generation), similar to human samples containing emicizumab. Emicizumab doses of 1.5 mg/kg and higher significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice. However, reduction was incomplete compared with mice treated with human FVIII concentrate, and no difference in efficacy between doses was observed. From this model, we deducted FVIII-like activity from emicizumab that corresponded to a dose of 4.5 U of FVIII per kilogram (ie, 9.0 U/dL). Interestingly, combined with a low FVIII dose (5 U/kg), emicizumab provided enough additive activity to allow complete bleeding arrest. This model could be useful for further in vivo analysis of emicizumab.
引用
- Ferrière S, Peyron I, Christophe OD, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020. PMID: 32369559. doi:10.1182/blood.2019004334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。